Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.53 |
| ▸ | CTSD | P07339 | 19/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 19/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255927 | 1.00 | BACE1 (0.53) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL10143717 | 0.94 | BACE1 (0.56) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL165255 | 0.92 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL165254 | 0.92 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL165991 | 0.91 | BACE1 (0.56) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL716702 | 0.91 | BACE1 (0.56) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL166863 | 0.91 | BACE1 (0.54) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL166862 | 0.91 | BACE1 (0.54) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL718961 | 0.91 | BACE1 (0.56) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL164641 | 0.91 | BACE1 (0.56) | BACE1CTSDBACE2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | claimed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | claimed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | claimed |
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 138/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.